Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...

Merck has entered a definitive agreement to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn.

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Verona Pharma plc, a biopharmaceutical company ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Merck, through a subsidiary, will acquire Verona Pharma for a total transaction value of approximately $10 billion.